AHI has struck a deal with Activate Health expanding into the Northern European nation of Estonia, delivering the world’s first AI-driven digital therapeutics platform for treating metabolic syndrome, affecting more than 500,000 Australians and nearly a third of the world’s adult population.
Activate’s software, aimed at preventing, controlling and reversing the group of conditions, is hoped to help manage the disease commonly diagnosed in people aged 50 years and older.
It will provide both patients and specialists with the necessary tools to delay the onset of chronic diseases, such as cardiovascular disease and type 2 diabetes.
The smartphone friendly software will leverage the human scanning technology platform MultiScan, which boasts a diverse range of data-driven applications across a breadth of industries.
“This will help us accelerate the development of our platform, including the integration of the AHI solution together with world-class data scientists, engineers, and medical experts,” founder and chief executive Siim Saare said.
“We will develop a novel health risk prediction model and AI-driven decision support system for the prevention and early intervention of chronic disease. We are looking forward to the journey ahead with AHI and our project partners.”
AHI’s Australian Stock Exchange-listed price has risen 1.63 per cent today, currently trading at 62.5c (10:34 am UTC+8 hours)